All News

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

Catch up on important pain management news from the month of September 2024.

In case you missed it, this week we had stories about pharmacists overcoming substance use disorder, the first new treatment approved for schizophrenia in decades, the Senate-Novo Nordisk hearing on semaglutide prices, and more.

Check out these important FDA updates from the month of September 2024.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL4 and IL13 pathways.

The approval of xanomeline and trospium chloride (Cobenfy) from Bristol Myers Squibb represents a “transformative moment in the treatment of schizophrenia.”

Without financial incentives, some senators expressed concerns that pharmaceutical research and development would stall.

Genentech said it’s sharing the data with global health authorities to make the therapy available to patients as soon as possible.

In the TEMPO-1 trial, both tavapadon doses effectively reduced motor symptoms in patients with early-stage Parkinson's disease.

Study findings raise concern about increased pain and disability, poorer pain self-management, and impaired quality of life during adolescence that can continue into young adulthood.

Check out this list of our top 10 stories from September 2024.

Senators sought to uncover why prices of Novo Nordisk’s GLP-1 receptor agonist semaglutide are significantly higher in the US compared with countries in Europe.

Catch up on important immunization news from the month of September.

Pharmacy professionals are at an increased risk of substance abuse due to many factors, but long-term recovery can be achieved with the help of specialized recovery networks.

The approval comes shortly after the FDA approved arimoclomol from Zevra Therapeutics to treat neurological manifestations of the disease in combination with miglustat.

Higher doses of buprenorphine may also be more effective against the increasing prevalence of fentanyl in the opioid crisis.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Henry and Jade Ranger of The Prescription Shoppe in Williamsburg, Virginia, discussed their practice and what it’s like operating a business together.

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the role his company plays in the ongoing issue of rising drug prices.

Check out these featured Drug Topics interviews from September 2024.

The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.

Eroxon topical gel addresses a significant unmet need for men experiencing erectile dysfunction.

“Pharmacies are processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving neffy,” said Eric Karas, CCO of ARS Pharmaceuticals.

LEO Pharma expects the regulatory review process to be completed in the second half of 2025.

Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.

Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.

In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.

In its first move since the July interim report detailing pharmacy benefit manager practices, the FTC is now suing CVS Caremark, Express Scripts, and Optum Rx.

Zevra Therapeutics said it expects the therapy to be commercially available in the United States in 8 to 12 weeks.